Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: An analysis of asthma exacerbations

Jonathan Matz, Amanda Emmett, Kathleen Rickard, Christopher Kalberg

Research output: Contribution to journalArticle

Abstract

Background: Adding salmeterol to low-dose fluticasone propionate (FP) produces greater improvements in pulmonary function and symptom control than increasing the dose of FP in patients who remain symptomatic with low-dose FP. Objective: We sought to compare the rates and characteristics of asthma exacerbations in patients after adding salmeterol to low-dose FP with the rates and characteristics of exacerbations in patients receiving higher dose FP. Methods: In 2 multicenter, double-blind studies, 925 patients 12 years of age and older receiving 88 μg twice daily FP randomly received either 42 μg of salmeterol and 88 μg of FP or an increased dose of FP (220 μg) twice daily for 24 weeks. Exacerbation rates and clinical measures of asthma worsening were assessed for all patients who experienced an asthma exacerbation. Results: The addition of salmeterol resulted in a significantly lower rate and number of exacerbations compared with higher dose FP. A total of 41 (8.8%) patients experienced 47 exacerbations with the addition of salmeterol compared with 63 (13.8%) patients with 75 exacerbations in the group receiving increased-dose FP (P = .017). Salmeterol plus low-dose FP was significantly more protective than increased-dose FP in preventing asthma exacerbations, as assessed by the time to first exacerbation (P < .05). In both groups clinical indicators of worsening asthma showed parallel changes before asthma exacerbation, and greater improvements were observed after exacerbation with salmeterol compared with higher dose FP. Conclusion: Salmeterol plus low-dose FP was more effective than higher dose FP alone in reducing asthma exacerbations in patients with persistent asthma. The ability to detect deteriorating asthma and the severity of exacerbation was similar between groups.

Original languageEnglish (US)
Pages (from-to)783-789
Number of pages7
JournalJournal of Allergy and Clinical Immunology
Volume107
Issue number5 SUPPL.
DOIs
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Asthma
Salmeterol Xinafoate
Fluticasone
Double-Blind Method
Lung

Keywords

  • Asthma exacerbations
  • Fluticasone propionate
  • Inhaled corticosteroid
  • Long-acting β-agonist
  • Salmeterol xinafoate

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone : An analysis of asthma exacerbations. / Matz, Jonathan; Emmett, Amanda; Rickard, Kathleen; Kalberg, Christopher.

In: Journal of Allergy and Clinical Immunology, Vol. 107, No. 5 SUPPL., 01.01.2001, p. 783-789.

Research output: Contribution to journalArticle

Matz, Jonathan ; Emmett, Amanda ; Rickard, Kathleen ; Kalberg, Christopher. / Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone : An analysis of asthma exacerbations. In: Journal of Allergy and Clinical Immunology. 2001 ; Vol. 107, No. 5 SUPPL. pp. 783-789.
@article{e56099a9a28e4b3591793f6169fe8848,
title = "Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: An analysis of asthma exacerbations",
abstract = "Background: Adding salmeterol to low-dose fluticasone propionate (FP) produces greater improvements in pulmonary function and symptom control than increasing the dose of FP in patients who remain symptomatic with low-dose FP. Objective: We sought to compare the rates and characteristics of asthma exacerbations in patients after adding salmeterol to low-dose FP with the rates and characteristics of exacerbations in patients receiving higher dose FP. Methods: In 2 multicenter, double-blind studies, 925 patients 12 years of age and older receiving 88 μg twice daily FP randomly received either 42 μg of salmeterol and 88 μg of FP or an increased dose of FP (220 μg) twice daily for 24 weeks. Exacerbation rates and clinical measures of asthma worsening were assessed for all patients who experienced an asthma exacerbation. Results: The addition of salmeterol resulted in a significantly lower rate and number of exacerbations compared with higher dose FP. A total of 41 (8.8{\%}) patients experienced 47 exacerbations with the addition of salmeterol compared with 63 (13.8{\%}) patients with 75 exacerbations in the group receiving increased-dose FP (P = .017). Salmeterol plus low-dose FP was significantly more protective than increased-dose FP in preventing asthma exacerbations, as assessed by the time to first exacerbation (P < .05). In both groups clinical indicators of worsening asthma showed parallel changes before asthma exacerbation, and greater improvements were observed after exacerbation with salmeterol compared with higher dose FP. Conclusion: Salmeterol plus low-dose FP was more effective than higher dose FP alone in reducing asthma exacerbations in patients with persistent asthma. The ability to detect deteriorating asthma and the severity of exacerbation was similar between groups.",
keywords = "Asthma exacerbations, Fluticasone propionate, Inhaled corticosteroid, Long-acting β-agonist, Salmeterol xinafoate",
author = "Jonathan Matz and Amanda Emmett and Kathleen Rickard and Christopher Kalberg",
year = "2001",
month = "1",
day = "1",
doi = "10.1067/mai.2001.114709",
language = "English (US)",
volume = "107",
pages = "783--789",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "5 SUPPL.",

}

TY - JOUR

T1 - Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone

T2 - An analysis of asthma exacerbations

AU - Matz, Jonathan

AU - Emmett, Amanda

AU - Rickard, Kathleen

AU - Kalberg, Christopher

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Background: Adding salmeterol to low-dose fluticasone propionate (FP) produces greater improvements in pulmonary function and symptom control than increasing the dose of FP in patients who remain symptomatic with low-dose FP. Objective: We sought to compare the rates and characteristics of asthma exacerbations in patients after adding salmeterol to low-dose FP with the rates and characteristics of exacerbations in patients receiving higher dose FP. Methods: In 2 multicenter, double-blind studies, 925 patients 12 years of age and older receiving 88 μg twice daily FP randomly received either 42 μg of salmeterol and 88 μg of FP or an increased dose of FP (220 μg) twice daily for 24 weeks. Exacerbation rates and clinical measures of asthma worsening were assessed for all patients who experienced an asthma exacerbation. Results: The addition of salmeterol resulted in a significantly lower rate and number of exacerbations compared with higher dose FP. A total of 41 (8.8%) patients experienced 47 exacerbations with the addition of salmeterol compared with 63 (13.8%) patients with 75 exacerbations in the group receiving increased-dose FP (P = .017). Salmeterol plus low-dose FP was significantly more protective than increased-dose FP in preventing asthma exacerbations, as assessed by the time to first exacerbation (P < .05). In both groups clinical indicators of worsening asthma showed parallel changes before asthma exacerbation, and greater improvements were observed after exacerbation with salmeterol compared with higher dose FP. Conclusion: Salmeterol plus low-dose FP was more effective than higher dose FP alone in reducing asthma exacerbations in patients with persistent asthma. The ability to detect deteriorating asthma and the severity of exacerbation was similar between groups.

AB - Background: Adding salmeterol to low-dose fluticasone propionate (FP) produces greater improvements in pulmonary function and symptom control than increasing the dose of FP in patients who remain symptomatic with low-dose FP. Objective: We sought to compare the rates and characteristics of asthma exacerbations in patients after adding salmeterol to low-dose FP with the rates and characteristics of exacerbations in patients receiving higher dose FP. Methods: In 2 multicenter, double-blind studies, 925 patients 12 years of age and older receiving 88 μg twice daily FP randomly received either 42 μg of salmeterol and 88 μg of FP or an increased dose of FP (220 μg) twice daily for 24 weeks. Exacerbation rates and clinical measures of asthma worsening were assessed for all patients who experienced an asthma exacerbation. Results: The addition of salmeterol resulted in a significantly lower rate and number of exacerbations compared with higher dose FP. A total of 41 (8.8%) patients experienced 47 exacerbations with the addition of salmeterol compared with 63 (13.8%) patients with 75 exacerbations in the group receiving increased-dose FP (P = .017). Salmeterol plus low-dose FP was significantly more protective than increased-dose FP in preventing asthma exacerbations, as assessed by the time to first exacerbation (P < .05). In both groups clinical indicators of worsening asthma showed parallel changes before asthma exacerbation, and greater improvements were observed after exacerbation with salmeterol compared with higher dose FP. Conclusion: Salmeterol plus low-dose FP was more effective than higher dose FP alone in reducing asthma exacerbations in patients with persistent asthma. The ability to detect deteriorating asthma and the severity of exacerbation was similar between groups.

KW - Asthma exacerbations

KW - Fluticasone propionate

KW - Inhaled corticosteroid

KW - Long-acting β-agonist

KW - Salmeterol xinafoate

UR - http://www.scopus.com/inward/record.url?scp=0035013066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035013066&partnerID=8YFLogxK

U2 - 10.1067/mai.2001.114709

DO - 10.1067/mai.2001.114709

M3 - Article

C2 - 11344343

AN - SCOPUS:0035013066

VL - 107

SP - 783

EP - 789

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 5 SUPPL.

ER -